Preview

PULMONOLOGIYA

Advanced search

Longterm low-dose therapy with macrolides in cystic fibrosis

Abstract

Background – Modulation of the immune response is an attractive alternative approach to therapy in CF. In this regard macrolides with their additional anti-inflammatory properties may be useful in the treatment of CF lung disease. Objective  – to assess action and potential mechanisms of long-term low-dose therapy with 15- and 14-member lactone ring macrolides in children with CF. Methods – Twenty-five CF patients (14 m, 11f; age range 6.5–16 yrs) were treated with azithromycin (SUMAMED®) in the dose 250 mg 2 times a week or clarithromycin in dose 250 mg every other day and basic therapy (ensymes; mucolytics, including rhDNAse; vitamins). The patients were routinely evaluated every three months. This evaluation included anthropometric measurements (Wt/Ht, %), physical examination, pulmonary function test (FEV1, FVC), microbiology of sputum (respiratory cultures), inflammatory markers in the sputum samples (neutrophil elastase activity, TNF-α, IL-4, IL-8, IFNγ concentrations) and in peripheral blood (sensitivity of lymphocytes to antiproliferative effect of glucocorticoids). Results – During the six-month period before the start of macrolides most patients had experienced a decline in FVC and FEV1 (-3.3±2% and -2±1.5% predicted, respectively). Following the treatment the lung disease progression became slower (FVC: 7.0±2.1% and FEV1: 7.1±2.1%, both p=0.02). The effect was more pronounced in the patients with FVC<70 %. Before macrolides treatment this subjects showed a loss of the mean semiannual changes in FVC (-6.0±3.0%) and FEV1 (-3.3±2.4%). After six month treatment with macrolides we noticed a significant improvement in lung function (FVC: 8.6±3.6 %, FEV1: 9.4±3.0%, both p=0.03). The patients with poor lung function showed an essential elevation of neutrophil elastase activity (from 60.0±15.1 to 130.1 ±30.4 U/mg protein; p=0.05) and decrease of TNF-β (from 68.0±34.1 to 9.3±2.3 lU/mg protein; p=0.02) in their sputum. Authors postulate that elastase activity elevation is associated with destruction of neutrophils following the antiinflammatory treatment. Discussion – Our preliminary findings suggest some potential mechanisms, by which long-term low-dose 15- and 14-member lactone ring macrolides therapy may be beneficial in CF.

About the Authors

T. V. Lubskaya
Медико-генетический научный центр РАМН
Russian Federation


N. I. Kapranov
Медико-генетический научный центр РАМН
Russian Federation


N. J. Kashirskaya
Медико-генетический научный центр РАМН
Russian Federation


L. A. Shabalova
Медико-генетический научный центр РАМН
Russian Federation


A. L. Pukhatsky
Медико-генетический научный центр РАМН
Russian Federation


G. V. Shmarina
Медико-генетический научный центр РАМН
Russian Federation


S. N. Kokarovtseva
Медико-генетический научный центр РАМН
Russian Federation


References

1. Страчунский Л.С., Козлов С.Н. Макролиды в современной клинической практике. Смоленск: Русич; 1998.

2. Певницкий Л Л ., Пухальский А.Л., Капранов Н.И. и др. Иммунологический мониторинг больных муковисцидозом. Значение различных лабораторных показателей. Вестн. РАМН 2000; 5: 40—46.

3. Самсыгина Г.А. Макролиды. В мире лекарств 1999; 3—4: 67—72.

4. Чучалин А.Г. Актуальные проблемы пульмонологии. В кн.: Сборник трудов Всероссийского науч. о-ва пульмонологов. М.; 2000. 362—373.

5. Labro М. Anti-inflammatory activity of macrolides: a new therapeutic potential? J. Antimicrob. Chemother. 1998; 41 (suppl.B): 37—46.

6. Anstead М., Kuhn R., Hartford L. et al. Effect of chronic azithromycin on lung function in cystic fibrosis. In: North American on cystic fibrosis conference. Berlin; 1999. Abstr. 421.

7. Pirzada O., Taylor C. Long term macrolide antibiotics improve pulmonary function in cystic fibrosis. Ibid. Abstr. 348.

8. Warner J.О. Immunology of cystic fibrosis. Br. Med. Bull. 1992; 48 (4): 893—911.

9. Hoiby N. Pseudomonas in cystic fibrosis: past, present, future: The Joseph Levy Memorial Lecture. Montreal; 1998.


Review

For citations:


Lubskaya T.V., Kapranov N.I., Kashirskaya N.J., Shabalova L.A., Pukhatsky A.L., Shmarina G.V., Kokarovtseva S.N. Longterm low-dose therapy with macrolides in cystic fibrosis. PULMONOLOGIYA. 2001;(3):41-45. (In Russ.)

Views: 246


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)